GlassScriptPhysician profile
Jonathan D Colino
NPI 1962736074
$787.76
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $385 · 2022: $273 · 2023: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $129.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $155.45 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $124.61 | 2021-2023 | Nuzyra |
| Astellas Pharma US INC | $122.99 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.34 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $45.23 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $40.42 | 2022-2023 | Farxiga |
| Abbvie INC. | $34.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.05 | 2022-2023 | Eliquis |
| Biohaven Pharmaceuticals, INC. | $24.93 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.60 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.08 | 2022 | |
| Boston Scientific Corporation | $20.95 | 2021 | |
| Mylan Specialty L.P. | $20.71 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.69 | 2021 | |
| Novo Nordisk INC | $16.86 | 2023 | Rybelsus, Ozempic |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Oxygen Therapy INC. | $15.76 | 2022 | |
| Exact Sciences Corporation | $13.37 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Colino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.